Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges
Journal of Clinical Medicine · 15.03.2024 · 13 (6) · 1694
DOI: 10.3390/jcm13061694 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.03.2024. Verfasst von Dennis Korthals und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department for Cardiology II, Electrophysiology, University Hospital Münster, 48149 Münster, Germany. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sarcoidosis is a multisystem disorder of unknown etiology. The leading hypothesis involves an antigen-triggered dysregulated T-cell-driven immunologic response leading to non-necrotic granulomas. In cardiac sarcoidosis (CS), the inflammatory response can lead to fibrosis, culminating in clinical manifestations such as atrioventricular block and ventricular arrhythmias. Cardiac manifestations frequently present as first and isolated signs or may appear in conjunction with extracardiac manifestations. The incidence of sudden cardiac death (SCD) is high. Diagnosis remains a challenge. For a definite diagnosis, endomyocardial biopsy (EMB) is suggested. In clinical practice, compatible findings in advanced imaging using cardiovascular magnetic resonance (CMR) and/or positron emission tomography (PET) in combination with extracardiac histological proof is considered sufficient. Management revolves around the control of myocardial inflammation by employing immunosuppression. However, data regarding efficacy are merely based on observational evidence. Prevention of SCD is of particular importance and several guidelines provide recommendations regarding device therapy. In patients with manifest CS, outcome data indicate a 5-year survival of around 90% and a 10-year survival in the range of 80%. Data for patients with silent CS are conflicting; some studies suggest an overall benign course of disease while others reported contrasting observations. Future research challenges involve better understanding of the immunologic pathogenesis of the disease for a targeted therapy, improving imaging to aid early diagnosis, assessing the need for screening of asymptomatic patients and randomized trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department for Cardiology II, Electrophysiology, University Hospital Münster, 48149 Münster, Germany.
- Department for Cardiology I, Division of Cardiovascular Imaging, University Hospital Münster, 48149 Münster, Germany.
- Department of Nuclear Medicine, University Hospital Münster, 48149 Münster, Germany.
- Department of Hematology, Hemostaseology, Oncology and Pneumology, Division of Pneumology, University Hospital Münster, 48149 Münster, Germany.
ORCID-Profile: Florian Doldi, David Ventura, Felix Wegner
Zitieren
APA
Korthals, D., Bietenbeck, M., Könemann, H., Doldi, F., Ventura, D., Schäfers, M., Mohr, M., Wolfes, J., Wegner, F., Yilmaz, A., & Eckardt, L. (2024). Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges. Journal of Clinical Medicine, 13(6), 1694. https://doi.org/10.3390/jcm13061694
Vancouver
Korthals D, Bietenbeck M, Könemann H, Doldi F, Ventura D, Schäfers M, et al. Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges. Journal of Clinical Medicine. 2024;13(6):1694. doi:10.3390/jcm13061694
BibTeX
@article{Korthals2024,
author = {Korthals, Dennis and Bietenbeck, Michael and Könemann, Hilke and Doldi, Florian and Ventura, David and Schäfers, Michael and Mohr, Michael and Wolfes, Julian and Wegner, Felix and Yilmaz, Ali and Eckardt, Lars},
title = {Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {6},
pages = {1694},
doi = {10.3390/jcm13061694}
}
EUVIMED